EGI
ADVM

EAM Global Investors’s Adverum Biotechnologies ADVM Stock Holding History

EAM Global Investors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,241
Closed -$1.93M – 129
2020
Q2 		$1.93M Sell
9,241
-4,522
-33% -$801K 0.87% 43
2020
Q1 		$1.34M Buy
+13,763
New +$1.6M 0.79% 62
2019
Q3 		– Sell
-14,085
Closed -$1.68M – 114
2019
Q2 		$1.68M Buy
+14,085
New +$1.17M 0.71% 58

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EAM Global Investors's ADVM Position: Q3 2020 in Review

EAM Global Investors sold out of Adverum Biotechnologies (ADVM) in Q3 2020, closing a stake of 9,241 shares — an estimated $1.93M sold.

EAM Global Investors first reported a position in ADVM in Q2 2019 and held it in 3 quarters. The position peaked at $1.93M in Q2 2020. 160 funds tracked by Wall St. Rank hold ADVM as of Q3 2020.

  • EAM Global Investors reported no remaining Adverum Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • EAM Global Investors sold 9,241 Adverum Biotechnologies shares in Q3 2020, an estimated $1.93M.
  • EAM Global Investors first reported a position in Adverum Biotechnologies in Q2 2019 and held it in 3 quarters.
  • EAM Global Investors's Adverum Biotechnologies position peaked at $1.93M in Q2 2020.
  • 160 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2020.

Based on EAM Global Investors's 13F filing for Q3 2020, filed 13 Nov 2020.